Skip to main
TOI
TOI logo

TOI Stock Forecast & Price Target

TOI Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

The Oncology Institute Inc. has demonstrated strong annual growth rates of 24%, 28%, and 21% from 2022 to 2024, reflecting the expansion of clinics under management from 67 to 86. The partnership with Helios is expected to enhance margins significantly in 2026 and 2027, with anticipated margins returning to the 12%-15% range as contracts mature. Additionally, the overall oncology market's substantial spending exceeding $200 billion, with a projected growth rate of over 10% CAGR, positions the company favorably for continued revenue growth, particularly in high-demand regions such as Nevada and Florida.

Bears say

The Oncology Institute Inc. (TOI) is currently facing significant financial challenges, as evidenced by a notable decline in revenue contributions from key partnerships, particularly with HUM, which has dropped below 10%. Additionally, the company has experienced a substantial hit to gross margins due to contract losses in 2024, compounded by dispensary margins suffering from the elimination of DIR fees, amounting to a $15 million negative impact. Furthermore, TOI's revenue growth trend significantly lags behind the industry average in oncology, indicating potential stagnation, while cash levels are alarmingly close to covenant thresholds, raising concerns about the company’s financial stability moving forward.

TOI has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of The Oncology Institute and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About The Oncology Institute (TOI) Forecast

Analysts have given TOI a Strong Buy based on their latest research and market trends.

According to 3 analysts, TOI has a Strong Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

The Oncology Institute (TOI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.